Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
- PMID: 32369612
- DOI: 10.1111/bjh.16787
Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
Keywords: COVID-19; cytokine release syndrome; interleukin-6; myeloma; tocilizumab.
References
-
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.2020 [Epub ahead of print]. https://doi.org/10.1056/NEJMoa2002032.
-
- Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Nati Sci Rev. 2020 [Epub ahead of print]. https://doi.org/10.1093/nsr/nwaa041.
-
- Castilletti C, Bordi L, Lalle E, Rozera G, Poccia F, Agrati C, et al. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virology. 2005;341:163-9.
-
- Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174:7977-85.
-
- Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473-4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical